Serum Levels of Cancer Antigen 125 before Hormone Replacement Therapy are not Associated with the Clinical Outcome of Frozen Embryo Transfer Cycles among Women with Adenomyosis

Abstract

Background: Serum levels of cancer antigen 125 (CA125) are reportedly closely associated with the extent of adenomyosis. However, the association between serum CA125 levels before hormone replacement therapy (HRT) and the clinical outcome of frozen embryo transfer (FET) in patients with adenomyosis is unknown.Methods: A total of 509 women with adenomyosis undergoing in vitro fertilization/intracytoplasmic sperm injection treatment between January 2013 and April 2019 were screened. Following the inclusion and exclusion criteria, the included patients were divided into two groups based on the serum CA125 levels (≤ or >35 IU/ml) before HRT. The basic characteristics and main outcomes of the two groups were compared.A receiver operating characteristic curve was used to evaluate the ability of serum CA125 levels before HRT to predict the clinical outcomes of FET. Besides, data were also separately analyzed in the GnRH agonist pretreatment subgroup. Results: There were no significant differences in clinical outcomes between the two groups of women before HRT. A receiver operating characteristic curve demonstrated that CA125 levels were not predictive of clinical pregnancy outcomes. Conclusions: Serum CA125 levels before HRT were not associated with the clinical outcomes of FET among women with adenomyosis. Hence, the discovery of other new markers is necessary.